Asset
PCS-499
Processa Pharmaceuticals Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04800562 | phase2 | terminated | 2021-04-12 | 2023-02-28 | Processa Pharmaceuticals | A Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica |
| NCT03698864 | phase2 | completed | 2018-11-07 | 2020-02-25 | Processa Pharmaceuticals | A Study to Evaluate the Safety and Tolerability of PCS499 for the Treatment of Necrobiosis Lipoidica |
| NCT03836222 | phase1 | completed | 2018-02-26 | 2018-06-04 | Processa Pharmaceuticals | Study to Evaluate the PK of Single and Optional Multiple Dosing Regimens of MR Formulations of PCS499 Compared to Trental® Administered to Healthy Subjects |
FDA applications (0)
This company has no applications containing this asset.